Should you buy Halozyme Therapeutics stock? (NasdaqGS:HALO). Let's see how it does in our automated value investing analysis system.
(Halozyme Therapeutics stock price per share)
|PE Ratio versus Sector||55% higher than other Healthcare stocks|
|PE Ratio versus Industry||45% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||21%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 6,466,845 shares shorted. With 140,917,965 shares available for purchase and an average trading volume over the past 10 trading days of 741,730, it would take at least 8.719 days for all of the short holders to cover their shorts.
Based on our analysis, we believe that you should not buy Halozyme Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Does Halozyme Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles